Concepts (264)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Aging | 31 | 2023 | 1544 | 3.060 |
Why?
|
| Alzheimer Disease | 33 | 2024 | 2109 | 3.020 |
Why?
|
| Cognitive Dysfunction | 17 | 2024 | 1061 | 2.100 |
Why?
|
| Hospitalization | 5 | 2019 | 300 | 1.710 |
Why?
|
| Cognition | 21 | 2024 | 1339 | 1.600 |
Why?
|
| Dementia | 11 | 2024 | 560 | 1.550 |
Why?
|
| Aged, 80 and over | 55 | 2024 | 4777 | 1.550 |
Why?
|
| Health Literacy | 7 | 2018 | 108 | 1.450 |
Why?
|
| Independent Living | 12 | 2022 | 322 | 1.290 |
Why?
|
| Aged | 59 | 2024 | 8997 | 1.250 |
Why?
|
| Female | 62 | 2024 | 15212 | 1.090 |
Why?
|
| Male | 62 | 2024 | 14772 | 1.050 |
Why?
|
| Activities of Daily Living | 10 | 2022 | 595 | 1.020 |
Why?
|
| Cohort Studies | 20 | 2024 | 1890 | 0.910 |
Why?
|
| Humans | 76 | 2024 | 27072 | 0.910 |
Why?
|
| Decision Making | 12 | 2016 | 223 | 0.870 |
Why?
|
| Brain | 15 | 2024 | 1649 | 0.860 |
Why?
|
| Economics | 3 | 2018 | 18 | 0.820 |
Why?
|
| Longitudinal Studies | 17 | 2023 | 1368 | 0.730 |
Why?
|
| DNA-Binding Proteins | 5 | 2022 | 276 | 0.730 |
Why?
|
| Work | 1 | 2020 | 6 | 0.710 |
Why?
|
| Social Behavior | 2 | 2011 | 67 | 0.710 |
Why?
|
| Women | 1 | 2020 | 14 | 0.700 |
Why?
|
| TDP-43 Proteinopathies | 2 | 2021 | 112 | 0.630 |
Why?
|
| National Institute on Aging (U.S.) | 1 | 2019 | 17 | 0.620 |
Why?
|
| Emergencies | 1 | 2019 | 32 | 0.610 |
Why?
|
| Social Participation | 2 | 2022 | 12 | 0.550 |
Why?
|
| Cognition Disorders | 5 | 2016 | 985 | 0.550 |
Why?
|
| Neuropsychological Tests | 15 | 2021 | 1196 | 0.550 |
Why?
|
| Interpersonal Relations | 3 | 2014 | 101 | 0.550 |
Why?
|
| Information Literacy | 2 | 2014 | 9 | 0.540 |
Why?
|
| Biomarkers | 2 | 2020 | 562 | 0.540 |
Why?
|
| Risk Assessment | 1 | 2019 | 624 | 0.510 |
Why?
|
| United States | 9 | 2024 | 2035 | 0.500 |
Why?
|
| Motor Activity | 3 | 2013 | 323 | 0.490 |
Why?
|
| Delay Discounting | 1 | 2015 | 24 | 0.470 |
Why?
|
| Risk Reduction Behavior | 1 | 2015 | 40 | 0.470 |
Why?
|
| Social Environment | 2 | 2011 | 76 | 0.450 |
Why?
|
| Trust | 1 | 2014 | 12 | 0.440 |
Why?
|
| Fraud | 1 | 2014 | 21 | 0.440 |
Why?
|
| Caregivers | 10 | 2008 | 197 | 0.430 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2020 | 164 | 0.420 |
Why?
|
| Mental Health | 2 | 2014 | 108 | 0.420 |
Why?
|
| Age Factors | 8 | 2020 | 766 | 0.410 |
Why?
|
| Medicare | 4 | 2024 | 118 | 0.400 |
Why?
|
| Educational Status | 6 | 2020 | 293 | 0.380 |
Why?
|
| Association | 1 | 2011 | 7 | 0.380 |
Why?
|
| Lewy Body Disease | 1 | 2012 | 97 | 0.360 |
Why?
|
| Mobility Limitation | 2 | 2012 | 94 | 0.360 |
Why?
|
| Cerebral Infarction | 1 | 2012 | 147 | 0.360 |
Why?
|
| Diet, Mediterranean | 2 | 2023 | 100 | 0.340 |
Why?
|
| Risk Factors | 10 | 2022 | 2302 | 0.340 |
Why?
|
| Risk | 4 | 2015 | 204 | 0.340 |
Why?
|
| Loneliness | 3 | 2023 | 59 | 0.310 |
Why?
|
| Follow-Up Studies | 8 | 2019 | 1792 | 0.300 |
Why?
|
| Residence Characteristics | 5 | 2016 | 214 | 0.300 |
Why?
|
| Middle Aged | 18 | 2019 | 8923 | 0.290 |
Why?
|
| Memory | 6 | 2018 | 297 | 0.290 |
Why?
|
| Prospective Studies | 6 | 2019 | 1778 | 0.280 |
Why?
|
| Sex Factors | 7 | 2020 | 464 | 0.280 |
Why?
|
| Autopsy | 5 | 2021 | 344 | 0.280 |
Why?
|
| Apolipoprotein E4 | 4 | 2022 | 263 | 0.280 |
Why?
|
| Brain Infarction | 2 | 2018 | 75 | 0.270 |
Why?
|
| Quality of Life | 3 | 2012 | 629 | 0.250 |
Why?
|
| Proportional Hazards Models | 4 | 2016 | 347 | 0.250 |
Why?
|
| Mental Competency | 4 | 2008 | 9 | 0.250 |
Why?
|
| Mental Status and Dementia Tests | 3 | 2020 | 56 | 0.240 |
Why?
|
| Social Isolation | 2 | 2023 | 30 | 0.240 |
Why?
|
| Chicago | 7 | 2021 | 949 | 0.230 |
Why?
|
| Apolipoproteins E | 3 | 2023 | 251 | 0.230 |
Why?
|
| Genotype | 2 | 2018 | 346 | 0.220 |
Why?
|
| Family | 2 | 2020 | 103 | 0.220 |
Why?
|
| Income | 3 | 2022 | 80 | 0.220 |
Why?
|
| Amyloid beta-Peptides | 5 | 2024 | 324 | 0.210 |
Why?
|
| Neuroimaging | 2 | 2021 | 126 | 0.200 |
Why?
|
| Psychiatric Status Rating Scales | 4 | 2016 | 310 | 0.190 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2022 | 22 | 0.190 |
Why?
|
| Clinical Trials as Topic | 1 | 2002 | 216 | 0.190 |
Why?
|
| Adaptation, Psychological | 1 | 2022 | 175 | 0.180 |
Why?
|
| Disease Progression | 4 | 2020 | 673 | 0.180 |
Why?
|
| Patient Participation | 4 | 2008 | 47 | 0.180 |
Why?
|
| Politics | 3 | 2008 | 11 | 0.180 |
Why?
|
| Depression | 3 | 2015 | 444 | 0.180 |
Why?
|
| Financing, Personal | 3 | 2018 | 22 | 0.170 |
Why?
|
| Social Segregation | 1 | 2020 | 7 | 0.170 |
Why?
|
| Cross-Sectional Studies | 8 | 2022 | 891 | 0.170 |
Why?
|
| Employment | 1 | 2020 | 38 | 0.170 |
Why?
|
| Cognitive Reserve | 1 | 2021 | 39 | 0.170 |
Why?
|
| Personality | 1 | 2021 | 53 | 0.170 |
Why?
|
| Brain Diseases | 1 | 2021 | 66 | 0.170 |
Why?
|
| Arteriolosclerosis | 2 | 2021 | 78 | 0.170 |
Why?
|
| Socioeconomic Factors | 2 | 2018 | 302 | 0.160 |
Why?
|
| Awareness | 1 | 2020 | 42 | 0.160 |
Why?
|
| Cognitive Aging | 1 | 2020 | 78 | 0.160 |
Why?
|
| Memory Disorders | 1 | 2020 | 159 | 0.160 |
Why?
|
| Disability Evaluation | 2 | 2011 | 264 | 0.160 |
Why?
|
| Hospitals, Low-Volume | 1 | 2018 | 6 | 0.150 |
Why?
|
| Hospitals, High-Volume | 1 | 2018 | 8 | 0.150 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2018 | 381 | 0.150 |
Why?
|
| Models, Neurological | 1 | 2018 | 25 | 0.150 |
Why?
|
| Research Subjects | 2 | 2008 | 10 | 0.150 |
Why?
|
| Immunocompromised Host | 1 | 2018 | 46 | 0.150 |
Why?
|
| Mutation | 1 | 2020 | 348 | 0.150 |
Why?
|
| Blood Glucose | 1 | 2018 | 104 | 0.150 |
Why?
|
| Neural Pathways | 1 | 2018 | 63 | 0.150 |
Why?
|
| Nervous System Diseases | 1 | 2019 | 117 | 0.140 |
Why?
|
| Neurofibrillary Tangles | 4 | 2022 | 193 | 0.140 |
Why?
|
| Regression Analysis | 2 | 2015 | 260 | 0.140 |
Why?
|
| Hospital Mortality | 1 | 2018 | 130 | 0.140 |
Why?
|
| Prevalence | 2 | 2012 | 443 | 0.140 |
Why?
|
| White Matter | 2 | 2016 | 134 | 0.140 |
Why?
|
| Learning | 2 | 2016 | 71 | 0.140 |
Why?
|
| Stress, Psychological | 2 | 2016 | 235 | 0.140 |
Why?
|
| Exercise | 1 | 2021 | 450 | 0.140 |
Why?
|
| Sepsis | 1 | 2018 | 113 | 0.140 |
Why?
|
| Ambulatory Care | 1 | 2017 | 69 | 0.140 |
Why?
|
| Informed Consent | 2 | 2008 | 23 | 0.130 |
Why?
|
| Cerebrovascular Disorders | 1 | 2018 | 133 | 0.130 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2018 | 167 | 0.130 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2016 | 12 | 0.130 |
Why?
|
| RNA Splicing | 1 | 2016 | 10 | 0.130 |
Why?
|
| Adult | 6 | 2022 | 7831 | 0.130 |
Why?
|
| LDL-Receptor Related Proteins | 1 | 2016 | 15 | 0.130 |
Why?
|
| Intelligence | 1 | 2016 | 18 | 0.130 |
Why?
|
| Gray Matter | 1 | 2016 | 50 | 0.130 |
Why?
|
| Interview, Psychological | 2 | 2008 | 41 | 0.130 |
Why?
|
| Incidence | 3 | 2016 | 759 | 0.130 |
Why?
|
| Comprehension | 1 | 2016 | 31 | 0.120 |
Why?
|
| Chronic Disease | 1 | 2017 | 415 | 0.120 |
Why?
|
| Alleles | 2 | 2018 | 216 | 0.120 |
Why?
|
| Health Behavior | 2 | 2014 | 159 | 0.120 |
Why?
|
| Crime Victims | 1 | 2016 | 32 | 0.120 |
Why?
|
| Amyloid | 3 | 2021 | 56 | 0.120 |
Why?
|
| Time Factors | 3 | 2014 | 1433 | 0.120 |
Why?
|
| Psychological Tests | 1 | 2015 | 52 | 0.120 |
Why?
|
| Racism | 1 | 2015 | 31 | 0.110 |
Why?
|
| Poverty | 1 | 2015 | 96 | 0.110 |
Why?
|
| Music | 1 | 2014 | 23 | 0.110 |
Why?
|
| Minority Groups | 1 | 2015 | 80 | 0.110 |
Why?
|
| Multilingualism | 1 | 2014 | 21 | 0.110 |
Why?
|
| Neoplasms | 1 | 2017 | 237 | 0.110 |
Why?
|
| tau Proteins | 3 | 2022 | 232 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 175 | 0.110 |
Why?
|
| Social Support | 2 | 2015 | 196 | 0.110 |
Why?
|
| Odds Ratio | 4 | 2018 | 270 | 0.110 |
Why?
|
| Parkinsonian Disorders | 1 | 2016 | 225 | 0.100 |
Why?
|
| Neprilysin | 1 | 2012 | 11 | 0.100 |
Why?
|
| Automobile Driving | 1 | 2012 | 20 | 0.100 |
Why?
|
| Actigraphy | 1 | 2012 | 100 | 0.100 |
Why?
|
| Disabled Persons | 1 | 2013 | 122 | 0.090 |
Why?
|
| Lewy Bodies | 3 | 2018 | 192 | 0.090 |
Why?
|
| Muscle Strength | 1 | 2012 | 130 | 0.090 |
Why?
|
| Vascular Diseases | 1 | 2011 | 42 | 0.090 |
Why?
|
| Environmental Health | 1 | 2010 | 8 | 0.090 |
Why?
|
| Motor Skills Disorders | 1 | 2010 | 15 | 0.090 |
Why?
|
| Health Status | 2 | 2012 | 218 | 0.090 |
Why?
|
| Phobic Disorders | 1 | 2010 | 66 | 0.080 |
Why?
|
| Severity of Illness Index | 2 | 2005 | 879 | 0.080 |
Why?
|
| Urban Population | 1 | 2011 | 153 | 0.080 |
Why?
|
| Third-Party Consent | 1 | 2008 | 1 | 0.070 |
Why?
|
| Ethics, Research | 1 | 2008 | 3 | 0.070 |
Why?
|
| Body Mass Index | 1 | 2011 | 458 | 0.070 |
Why?
|
| Assisted Living Facilities | 1 | 2008 | 6 | 0.070 |
Why?
|
| Surveys and Questionnaires | 2 | 2021 | 1144 | 0.070 |
Why?
|
| Attitude | 1 | 2008 | 34 | 0.070 |
Why?
|
| Nursing Homes | 1 | 2008 | 36 | 0.070 |
Why?
|
| Health Services Needs and Demand | 1 | 2008 | 43 | 0.070 |
Why?
|
| Delivery of Health Care | 2 | 2015 | 144 | 0.070 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2008 | 55 | 0.070 |
Why?
|
| Selegiline | 1 | 2005 | 2 | 0.060 |
Why?
|
| alpha-Tocopherol | 1 | 2005 | 13 | 0.060 |
Why?
|
| Mood Disorders | 1 | 2005 | 27 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2018 | 587 | 0.060 |
Why?
|
| Physician-Patient Relations | 1 | 2005 | 44 | 0.060 |
Why?
|
| Civil Rights | 1 | 2004 | 2 | 0.060 |
Why?
|
| Self Report | 2 | 2016 | 223 | 0.060 |
Why?
|
| Healthy Lifestyle | 1 | 2024 | 45 | 0.050 |
Why?
|
| Illinois | 2 | 2015 | 250 | 0.050 |
Why?
|
| Statistics as Topic | 2 | 2015 | 105 | 0.050 |
Why?
|
| Vitamins | 1 | 2022 | 19 | 0.050 |
Why?
|
| Vitamin D | 1 | 2022 | 39 | 0.050 |
Why?
|
| Unconsciousness | 1 | 2022 | 9 | 0.050 |
Why?
|
| Infarction | 1 | 2022 | 29 | 0.050 |
Why?
|
| Anthocyanins | 1 | 2022 | 11 | 0.050 |
Why?
|
| Sclerosis | 1 | 2022 | 66 | 0.050 |
Why?
|
| Fruit | 1 | 2022 | 27 | 0.050 |
Why?
|
| Logistic Models | 2 | 2018 | 395 | 0.050 |
Why?
|
| Motor Skills | 1 | 2021 | 48 | 0.050 |
Why?
|
| Individuality | 1 | 2021 | 23 | 0.040 |
Why?
|
| Neuroticism | 1 | 2021 | 32 | 0.040 |
Why?
|
| Southeastern United States | 1 | 2020 | 14 | 0.040 |
Why?
|
| Midwestern United States | 1 | 2020 | 48 | 0.040 |
Why?
|
| Religion | 1 | 2019 | 41 | 0.040 |
Why?
|
| Multilevel Analysis | 1 | 2018 | 7 | 0.040 |
Why?
|
| Heterozygote | 1 | 2018 | 100 | 0.040 |
Why?
|
| Neuropathology | 1 | 2018 | 81 | 0.040 |
Why?
|
| Hippocampus | 1 | 2020 | 273 | 0.040 |
Why?
|
| Critical Care | 1 | 2018 | 117 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2017 | 27 | 0.030 |
Why?
|
| Mental Status Schedule | 2 | 2008 | 90 | 0.030 |
Why?
|
| Length of Stay | 1 | 2018 | 313 | 0.030 |
Why?
|
| Vulnerable Populations | 1 | 2016 | 23 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2021 | 1112 | 0.030 |
Why?
|
| Plaque, Amyloid | 1 | 2017 | 145 | 0.030 |
Why?
|
| Frontal Lobe | 1 | 2016 | 81 | 0.030 |
Why?
|
| Anisotropy | 1 | 2016 | 44 | 0.030 |
Why?
|
| Temporal Lobe | 1 | 2016 | 83 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2016 | 71 | 0.030 |
Why?
|
| Diagnosis | 1 | 2015 | 24 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 219 | 0.030 |
Why?
|
| Epidemiologic Methods | 1 | 2015 | 17 | 0.030 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2016 | 89 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2016 | 164 | 0.030 |
Why?
|
| Demography | 1 | 2015 | 72 | 0.030 |
Why?
|
| Cities | 1 | 2015 | 15 | 0.030 |
Why?
|
| Financial Management | 1 | 2015 | 23 | 0.030 |
Why?
|
| Life Change Events | 1 | 2014 | 37 | 0.030 |
Why?
|
| Memory, Episodic | 1 | 2016 | 116 | 0.030 |
Why?
|
| Empathy | 1 | 2014 | 39 | 0.030 |
Why?
|
| Mental Recall | 1 | 2014 | 62 | 0.030 |
Why?
|
| Language | 1 | 2014 | 63 | 0.030 |
Why?
|
| Spouses | 2 | 2005 | 32 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 599 | 0.030 |
Why?
|
| Spatial Behavior | 1 | 2012 | 9 | 0.020 |
Why?
|
| Licensure | 1 | 2012 | 9 | 0.020 |
Why?
|
| Accidents, Traffic | 1 | 2012 | 23 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2012 | 21 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 2012 | 15 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2012 | 23 | 0.020 |
Why?
|
| Environment | 1 | 2012 | 42 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2012 | 53 | 0.020 |
Why?
|
| Transfection | 1 | 2012 | 121 | 0.020 |
Why?
|
| Mice | 1 | 2016 | 1395 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2012 | 260 | 0.020 |
Why?
|
| Baltimore | 1 | 2011 | 9 | 0.020 |
Why?
|
| Linear Models | 1 | 2012 | 247 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2012 | 310 | 0.020 |
Why?
|
| Reaction Time | 1 | 2011 | 102 | 0.020 |
Why?
|
| Data Collection | 1 | 2011 | 91 | 0.020 |
Why?
|
| Executive Function | 1 | 2011 | 111 | 0.020 |
Why?
|
| Psychometrics | 1 | 2011 | 220 | 0.020 |
Why?
|
| Psychomotor Performance | 1 | 2011 | 205 | 0.020 |
Why?
|
| Survival Rate | 1 | 2010 | 342 | 0.020 |
Why?
|
| Animals | 1 | 2016 | 3642 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2008 | 102 | 0.020 |
Why?
|
| Observer Variation | 1 | 2008 | 96 | 0.020 |
Why?
|
| Simvastatin | 1 | 2008 | 14 | 0.020 |
Why?
|
| ROC Curve | 1 | 2008 | 141 | 0.020 |
Why?
|
| Prognosis | 1 | 2010 | 785 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2016 | 3485 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 482 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2008 | 292 | 0.020 |
Why?
|
| Professional-Family Relations | 1 | 2005 | 20 | 0.020 |
Why?
|
| Judgment | 1 | 2005 | 6 | 0.020 |
Why?
|
| Cost of Illness | 1 | 2005 | 50 | 0.020 |
Why?
|
| Nootropic Agents | 1 | 2005 | 14 | 0.020 |
Why?
|
| Policy Making | 1 | 2004 | 12 | 0.010 |
Why?
|
| Long-Term Care | 1 | 2004 | 59 | 0.010 |
Why?
|
| Patient Compliance | 1 | 2005 | 150 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2003 | 139 | 0.010 |
Why?
|
| Interviews as Topic | 1 | 2003 | 132 | 0.010 |
Why?
|
| Pennsylvania | 1 | 2002 | 7 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2002 | 94 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2003 | 676 | 0.010 |
Why?
|